Michael J. Tilby

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours

Ruth Plummer, Richard H. Wilson, Hilary Calvert et al. · British Journal of Cancer · 2011 · 381 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia

Elaine Willmore, Sarah de Caux, Nicola J. Sunter et al. · Blood · 2004 · 266 citations · Full text

Medicine, Oncology, Pharmacology +13

γH2AX Foci Form Preferentially in Euchromatin after Ionising-Radiation

Ian G. Cowell, Nicola J. Sunter, Prim B. Singh et al. · PLoS ONE · 2007 · 219 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Etoposide Targets Topoisomerase IIα and IIβ in Leukemic Cells: Isoform-Specific Cleavable Complexes Visualized and QuantifiedIn Situ by a Novel Immunofluorescence Technique

Elaine Willmore, Adrian Frank, Kay Padget et al. · Molecular Pharmacology · 1998 · 147 citations

Medicine, Oncology, Pharmacology +14

Murine Transgenic Cells Lacking DNA Topoisomerase IIβ Are Resistant to Acridines and Mitoxantrone: Analysis of Cytotoxicity and Cleavable Complex Formation

Elaine Willmore, Michael J. Tilby, L. Li et al. · Molecular Pharmacology · 1999 · 95 citations

Medicine, Cell Biology, Pharmacology +13